David Lewis
Stock Analyst at Morgan Stanley
(2.73)
# 2,070
Out of 4,996 analysts
271
Total ratings
67.18%
Success rate
9.44%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $127 → $137 | $132.34 | +3.52% | 25 | Jul 15, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $310.16 | -3.28% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $183.69 | +49.71% | 23 | Oct 11, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $66.61 | +36.62% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $750 → $720 | $14.76 | +4,778.05% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $22.34 | +347.73% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $114.34 | -86.88% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $1.69 | +1,675.15% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $67.08 | +11.81% | 11 | Feb 3, 2022 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $42 → $45 | $20.16 | +123.27% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $48.03 | +24.92% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $56.26 | +45.75% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $120.81 | +256.76% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $93.84 | +64.11% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $13.96 | +186.53% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $76.80 | +75.78% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $368.85 | -24.09% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $440.94 | -35.37% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $6.62 | +187.01% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $171.61 | -45.22% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $74.09 | +6.63% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $98.04 | +83.60% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $180.52 | +3.59% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $11.58 | +288.60% | 5 | Dec 15, 2020 |
Abbott Laboratories
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $127 → $137
Current: $132.34
Upside: +3.52%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $310.16
Upside: -3.28%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $183.69
Upside: +49.71%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $66.61
Upside: +36.62%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $750 → $720
Current: $14.76
Upside: +4,778.05%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $22.34
Upside: +347.73%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $114.34
Upside: -86.88%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $1.69
Upside: +1,675.15%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $67.08
Upside: +11.81%
Envista Holdings
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $20.16
Upside: +123.27%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $48.03
Upside: +24.92%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $56.26
Upside: +45.75%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $120.81
Upside: +256.76%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $93.84
Upside: +64.11%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $13.96
Upside: +186.53%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $76.80
Upside: +75.78%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $368.85
Upside: -24.09%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $440.94
Upside: -35.37%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $6.62
Upside: +187.01%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $171.61
Upside: -45.22%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $74.09
Upside: +6.63%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $98.04
Upside: +83.60%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $180.52
Upside: +3.59%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $11.58
Upside: +288.60%